Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2015, Article ID 285193, 10 pages
http://dx.doi.org/10.1155/2015/285193
Clinical Study

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

1Department of Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, MI 48201, USA
2Department of Medicine, Wayne State University, Detroit, MI 48201, USA
3Roger Williams Medical Center, Providence, RI 02908, USA
4Department of Pathology, Roger Williams Medical Center, Providence, RI 02908, USA
5Department of Immunology and Microbiology, Wayne State University, Detroit, MI 48201, USA

Received 10 November 2014; Revised 9 January 2015; Accepted 15 January 2015

Academic Editor: Hendrik Van Poppel

Copyright © 2015 Ulka Vaishampayan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [16 citations]

The following is the list of published articles that have cited the current article.

  • Chao-hui Hao, Qian-he Han, Zhong-jie Shan, Jian-ting Hu, Nan Zhang, and Xue-pei Zhang, “Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody,” Theoretical Biology and Medical Modelling, vol. 12, no. 1, 2015. View at Publisher · View at Google Scholar
  • Marc Diederich, Cindy Grandjenette, and Mario Dicato, “Bispecific antibodies: An innovative arsenal to hunt, grab and destroy cancer cells,” Current Pharmaceutical Biotechnology, vol. 16, no. 8, pp. 670–683, 2015. View at Publisher · View at Google Scholar
  • Divaya Bhutani, and Lawrence G. Lum, “Activated T cells armed with bispecific antibodies kill tumor targets,” Current Opinion in Hematology, vol. 22, no. 6, pp. 476–483, 2015. View at Publisher · View at Google Scholar
  • Eugene A Zhukovsky, Richard J Morse, and Marcela V Maus, “Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection,” Current Opinion in Immunology, vol. 40, pp. 24–35, 2016. View at Publisher · View at Google Scholar
  • A. Grant Schissler, Ikbel Achour, Haiquan Li, Walter W. Piegorsch, Yves A. Lussier, Qike Li, James L. Chen, Colleen Kenost, and D. Dean Billheimer, “Analysis of aggregated cell-cell statistical distances within pathways unveils therapeutic-resistance mechanisms in circulating tumor cells,” Bioinformatics, vol. 32, no. 12, pp. i80–i89, 2016. View at Publisher · View at Google Scholar
  • Lisa M. Cordes, James L. Gulley, and Ravi A. Madan, “The evolving role of immunotherapy in prostate cancer,” Current Opinion in Oncology, vol. 28, no. 3, pp. 232–240, 2016. View at Publisher · View at Google Scholar
  • Manish K. Thakur, and Ulka Vaishampayan, “Multifaceted and personalized therapy of advanced prostate cancer,” Current Opinion in Oncology, vol. 28, no. 3, pp. 222–231, 2016. View at Publisher · View at Google Scholar
  • Man Zhang, Pan Ma, Chenghai Zhao, Xin Xue, Huamin Han, Hua Tao, Weigang Xiu, Juan Ma, Changzhen Liu, and Jia Cai, “B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy,” Oncotarget, vol. 7, no. 20, pp. 29480–29491, 2016. View at Publisher · View at Google Scholar
  • Aifen Li, Jieyu Xing, Li Li, Changhua Zhou, Bin Dong, Ping He, Qing Li, and Zhong Wang, “A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells,” AMB Express, vol. 6, no. 1, 2016. View at Publisher · View at Google Scholar
  • Archana Thakur, and Lawrence G. Lum, ““NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results,” Expert Opinion on Biological Therapy, pp. 1–14, 2016. View at Publisher · View at Google Scholar
  • Lawrence G. Lum, Archana Thakur, Sri Vidya Kondadasula, Zaid Al-Kadhimi, Abhinav Deol, Elyse N. Tomaszewski, Hiroshi Yano, Dana L. Schalk, Lois Ayash, Jeffrey A. Zonder, Joseph P. Uberti, Muneer H. Abidi, and Voravit Ratanatharathorn, “Targeting Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity,” Biology of Blood and Marrow Transplantation, 2016. View at Publisher · View at Google Scholar
  • Shengnan Yu, Anping Li, Qian Liu, Xun Yuan, Hanxiao Xu, Dechao Jiao, Richard G. Pestell, Xinwei Han, and Kongming Wu, “Recent advances of bispecific antibodies in solid tumors,” Journal of Hematology & Oncology, vol. 10, no. 1, 2017. View at Publisher · View at Google Scholar
  • Ulka N. Vaishampayan, “Changing face of metastatic prostate cancer,” Current Opinion in Oncology, vol. 29, no. 3, pp. 196–200, 2017. View at Publisher · View at Google Scholar
  • Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, and Kongming Wu, “Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment,” Experimental Hematology & Oncology, vol. 6, no. 1, 2017. View at Publisher · View at Google Scholar
  • Lawrence G. Lum, and Catherine M. Bollard, “Specific Adoptive T-Cell Therapy for Viral and Fungal Infections,” Management of Infections in the Immunocompromised Host, pp. 395–411, 2018. View at Publisher · View at Google Scholar
  • Shima Moradi-Kalbolandi, Aysooda Hosseinzade, Malihe Salehi, Parnaz Merikhian, and Leila Farahmand, “Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER,” Journal of Pharmacy and Pharmacology, 2018. View at Publisher · View at Google Scholar